<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="institutions [3]. Until 2011, dual therapy using pegylated interferon and" exact="ribavirin" post="(PEG-IFN and RBV) was the standard course of treatment."/>
 <result pre="improvement in the SVR12 rate. Triple therapy with the DAA" exact="telaprevir" post="(TVR) or boceprevir (BOC) in combination with PEG-IFN and"/>
 <result pre="SVR12 rate. Triple therapy with the DAA telaprevir (TVR) or" exact="boceprevir" post="(BOC) in combination with PEG-IFN and RBV resulted in"/>
 <result pre="prior experience with treatment. The main DAA regimen used was" exact="sofosbuvir" post="(SOF) combined with ledipasvir (LDV) (±RBV) [9]. The model"/>
 <result pre="developed for treatment-naive patients treated with the DAAs SOF and/or" exact="simeprevir" post="(SMV). The ICER for Gissel et al. [43] is"/>
 <result pre="regimens and the interferon-based triple therapy, SOF with LDV and" exact="ombitasvir" post="(OBV) + paritaprevir (PTV) + ritonavir (RTV) + dasabuvir"/>
 <result pre="SOF with LDV and ombitasvir (OBV) + paritaprevir (PTV) +" exact="ritonavir" post="(RTV) + dasabuvir (DSV) ± RBV were the most"/>
 <result pre="and ombitasvir (OBV) + paritaprevir (PTV) + ritonavir (RTV) +" exact="dasabuvir" post="(DSV) ± RBV were the most cost-efficient alternatives. The"/>
 <result pre="multicenter trialJ. Viral Hepat.20152310511510.1111/jvh.1247126411532 24.SiebertU.SroczynskiG.RossolS.WasemJ.Ravens-SiebererU.KurthB.M.MannsM.P.McHutchisonJ.G.WongJ.B.Cost effectiveness of peginterferon alpha-2b plus" exact="ribavirin" post="versus interferon alpha-2b plus ribavirin for initial treatment of"/>
 <result pre="effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus" exact="ribavirin" post="for initial treatment of chronic hepatitis CGut20035242543210.1136/gut.52.3.42512584228 25.StahmeyerJ.JacobsS.RossolS.Heinrich WedemeyerH.WirthD.BianicF.KrauthC.Cost-effectiveness"/>
 <result pre="in Health CareCologne, Germany2017 30.GrishchenkoM.GrieveR.D.SweetingM.J.De AngelisD.ThomsonB.J.RyderS.D.IrvingW.L.Cost-effectiveness of pegylated interferon and" exact="ribavirin" post="for patients with chronic hepatitis C treated in routine"/>
 <result pre="of the liverAm. J. Gastroenterol.19979266728995940 36.CardosoA.-C.MoucariR.Figueiredo-MendesC.RipaultM.-P.GiuilyN.CastelnauC.BoyerN.AsselahT.Martinot-PeignouxM.MaylinS.et al.Impact of peginterferon and" exact="ribavirin" post="therapy on hepatocellular carcinoma: Incidence and survival in hepatitis"/>
 <result pre="95.75 ** €766.19/SVR12 Percentage Point * Mean of SVR12 rates" exact="boceprevir" post="+ pegylated interferon + ribavirin non-cirrhotic + cirrhotic [14];"/>
 <result pre="* Mean of SVR12 rates boceprevir + pegylated interferon +" exact="ribavirin" post="non-cirrhotic + cirrhotic [14]; ** Mean of SVR12 rates"/>
 <result pre="ribavirin non-cirrhotic + cirrhotic [14]; ** Mean of SVR12 rates" exact="sofosbuvir" post="+ ledipasvir ± ribavirin non-cirrhotic + cirrhotic [14]; ICER—incremental"/>
 <result pre="[14]; ** Mean of SVR12 rates sofosbuvir + ledipasvir ±" exact="ribavirin" post="non-cirrhotic + cirrhotic [14]; ICER—incremental cost-effectiveness ratio."/>
</results>
